Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience's stock (NAGE) experienced a name and ticker change on March 19, 2025. The stock price declined by 10.85% between March 19, 2025, and November 19, 2025. Niagen Bioscience reported record Q3 revenue, rising 33% year-over-year, beating estimates. On October 6, 2025, Niagen Bioscience increased its full-year 2025 net sales growth forecast to 25%-30% year-over-year. On November 13, 2025, the company launched Tru Niagen® Beauty and announced results from the first-ever randomized controlled trial exploring Niagen supplementation in long COVID. In November 2025, the company announced a new $10 million share repurchase program. As of November 5, 2025, Canaccord Genuity maintained a Buy recommendation for NAGE.

Information regarding specific demand seasonality for Niagen Bioscience, Inc.'s products and services was not found in the provided search results.

Niagen Bioscience, Inc., formerly ChromaDex Corporation, researches nicotinamide adenine dinucleotide (NAD+) and focuses on healthy aging products. The company's major products and services are categorized into consumer products, ingredients, and analytical reference standards and services. The consumer products segment offers dietary supplements containing proprietary ingredients, including Tru Niagen. The ingredients segment develops and commercializes proprietary ingredient technologies. The analytical reference standards and services segment provides phytochemical reference standards and other research and development services. The company also offers Niagen Plus, which includes pharmaceutical-grade intravenous (IV) and injectable formulations of Niagen.

Niagen Bioscience, Inc. is based in Los Angeles, California, United States. The company's primary distribution for its Tru Niagen products is within the United States, reaching consumers through its e-commerce platform, Amazon, ShopHQ, other internet marketplaces, specialty retailers, and direct healthcare practitioners. Niagen Plus is available at clinics nationwide in the U.S., including over 50 iCRYO locations.

Niagen Bioscience maintains a strong brand reputation rooted in its commitment to precision science and extensive research on NAD+. The announcement of results from the first-ever randomized controlled trial exploring Niagen supplementation in long COVID in November 2025 has positively highlighted the scientific backing and potential health benefits of its products. The launch of Tru Niagen Beauty in November 2025 demonstrates the company's innovation and expansion into new markets. The FDA's reversal of rulings on the DSHEA drug preclusion rule related to NMN in October 2025 has brought increased awareness to the NAD+ precursor market. The company has received a "Moderate Buy" consensus rating from analysts.

Niagen Bioscience (NAGE) has a significant portion of its stock owned by institutional investors, ranging from approximately 39.77% to 40.07%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Tieton Capital Management, LLC. Individual insider ownership is also substantial, with Hoi Shuen Solina Holly Chau being the largest individual shareholder, owning 25.67 million shares, representing 32.17% of the company.